Velox Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 148.92%
- Profit Growth 62.43%
- Ebitda 75.22%
- Net Worth -55.88%
- Total Assets -25.48%
About Velox Biotech
Velox Biotech Private Limited (VBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 23 November 2020 (Four years and two months 18 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sunil Sharma and Pooja Shukla serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909DL2020PTC373579
-
Company No.
373579
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Nov 2020
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Velox Biotech Private Limited offer?
Velox Biotech Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Biochemistry Analyzer, IVDs & Analyzers, Surgical & ICU Equipments, CPAP, BiPAP Machine & Accessories.
Who are the key members and board of directors at Velox Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Sharma
|
Director | 23-Nov-2020 | Current |
|
Pooja Shukla
|
Director | 23-Nov-2020 | Current |
Financial Performance of Velox Biotech.
Velox Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 148.92% increase. The company also saw a substantial improvement in profitability, with a 62.43% increase in profit. The company's net worth observed a substantial decline by a decrease of 55.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Velox Biotech?
In 2021, Velox Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Ivd Healthcare Private LimitedSunil Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Velox Biotech?
Velox Biotech has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Velox Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Velox Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
